Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...

Eli Lilly (NYSE:LLY) has launched its popular weight loss/diabetes therapy Mounjaro in India, beating its biggest rival, Novo ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Workouts at gyms to combat muscle loss caused by GLP-1 drugs are gaining traction, but do they differ from regular strength ...

Experts explain if Ozempic causes hair loss, and how the medication may indirectly lead to weight loss-related hair loss due ...

AFTER months of careful research, Jennifer Dootson started weight loss injections, hoping to end two decades of yo-yo dieting ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s ...

Eli Lilly has launched its much-anticipated diabetes and weight-loss drug, Mounjaro (tirzepatide), in India, offering a new ...